Follow The Filings

IMNM Immunome

Immunome earnings company data as of 7:50 PM ET 10/23

Limited consensus data for this ticker (thin coverage or data-plan limits). Dates may be company-announced rather than sell-side consensus. Calendar and recent prints remain the primary lens when available.

Scheduled

1 period, newest first, nothing reported yet. Each row shows EPS above revenue.

Period Date Metric Estimate Actual Result
FY2026 Q3 5 Nov EPS — — —
Rev — — —

Insider trades

Open-market buys and sales by IMNM's executives, directors and 10% owners in the last 12 months, from their Form 4s

All IMNM insider trades
  • $2.3M bought by 3 insiders
  • $1.5M sold by 2 insiders outside a trading plan
  • $26M sold by 5 insiders under 10b5-1 plans
  1. Jack Higgins Chief Scientific Officer
    Planned sale
    $334K 13,200 shares at $25.32 17% of stake
    Traded Sep 11 Filed Sep 15
    ↗
  2. Isaac Barchas Director
    Planned sale
    $2.2M 83,464 shares at $26.35
    Traded Aug 10–12 Filed Aug 12
    ↗
  3. Isaac Barchas Director
    Planned sale
    $940K 36,088 shares at $26.06 33% of stake
    Traded Aug 6–7 Filed Aug 10
    ↗
  4. Kinney Horn Chief Business Officer
    Planned sale
    $2.3M 90,616 shares at $25.09 100% of stake
    Traded Aug 4 Filed Aug 6
    ↗
  5. Kinney Horn Chief Business Officer
    Planned sale
    $27K 1,092 shares at $25.00 100% of stake
    Traded Jul 7 Filed Jul 9
    ↗
  6. Robert Lechleider Chief Medical Officer
    Planned sale
    $1.2M 55,000 shares at $22.62 78% of stake
    Traded Jul 2 Filed Jul 7
    ↗
  7. Isaac Barchas Director
    Planned sale
    $2.4M 100,000 shares at $24.13 48% of stake
    Traded Jul 6–7 Filed Jul 7
    ↗
  8. Isaac Barchas Director
    Planned sale
    $4.4M 201,050 shares at $21.85 49% of stake
    Traded Jun 30–Jul 2 Filed Jul 2
    ↗
  9. Robert Lechleider Chief Medical Officer
    Planned sale
    $1.1M 55,000 shares at $19.85 78% of stake
    Traded Jun 25 Filed Jun 29
    ↗
  10. Max Rosett CFO
    Planned sale
    $1.1M 60,000 shares at $18.23 53% of stake
    Traded Jun 15 Filed Jun 17
    ↗
  11. Jean Jacques Bienaime Director
    Sale
    $204K 10,500 shares at $19.41 24% of stake
    Traded Jun 5 Filed Jun 9
    ↗
  12. Jean Jacques Bienaime Director
    Buy
    $204K 10,500 shares at $19.45 +32% to stake
    Traded Jun 5 Filed Jun 9
    ↗
  13. Jean Jacques Bienaime Director
    Buy
    $104K 5,000 shares at $20.70 +13% to stake
    Traded May 15 Filed May 19
    ↗
  14. Max Rosett CFO
    Planned sale
    $1.4M 65,000 shares at $21.92 55% of stake
    Traded Apr 2 Filed Apr 3
    ↗
  15. Jack Higgins Chief Scientific Officer
    Planned sale
    $204K 9,438 shares at $21.64 30% of stake
    Traded Apr 2 Filed Apr 3
    ↗

Also filed in the last 12 months, not counted as buying or selling: 9 gifts, 9 option exercises, and 7 stock grants.

SEC filings

Recent issuer filings from EDGAR, 14 shown.

Filed Form Detail Links
8-K 1.01,3.02,9.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
8-K 5.07 Filing Doc
SCHEDULE 13G — Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
DEF 14A Filing Doc
DEFA14A Filing Doc

Source: SEC EDGAR submissions, updated 6 days ago. All on EDGAR

Estimates are consensus figures; SEC filings remain the official record. Not investment advice.